+91-8668442535

Multiple Myeloma Treatment Market, By Type (Drug Therapy, Stem Cell Transplantation, Biophosphonates, Radiation Therapy, & Surgical Therapy) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

The report titled "Multiple Myeloma Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration of 2015–2025. The research study in question provides an in-depth examination of multiple myeloma market segments based on the type and different geographies further subdivided by countries. According to Myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably, and release only one type of antibody known as paraprotein, which has no useful function. It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.

For the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into drug therapy, stem cell transplantation, bisphosphonates, radiation therapy, and surgical therapy. Drug therapy is further segmented into monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors, chemotherapy, histone deacetylase inhibitors, and corticosteroids. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the multiple myeloma treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The multiple myeloma treatment market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, and Juno Therapeutics, among others.

Based on the type of therapy, the global multiple myeloma market is segmented as follows:

  • Drugs Therapy
  • Monoclonal Antibodies
  • Daratumumab
  • Elotuzumab
  • Immunomodulatory Drugs
  • Lenalidomide
  • Pomalidomide
  • Thalidomide
  • Proteasome Inhibitors
  • Ixazomib
  • Bortezomib
  • Carfilzomib
  • Chemotherapy
  • Liposomes containing doxorubicin HCl
  • Melphalan
  • Cyclophosphamide
  • Histone deacetylase inhibitor
  • Panobinostat
  • Corticosteroids
  • Dexamethasone
  • Prednisone
  • Stem Cell Transplantation
  • Allogenic stem cell transplants
  • Autologous stem cell transplants
  • Bisphosphonates
  • Radiation Therapy
  • Surgical Therapy

In 2016, drug therapy dominated the market due to the incessant market entry of novel drug therapies, the most convenient mode of treatment, and the rising demand for targeted therapy and biological drugs. These drugs enhance the immune system cells that identify and attack cancer cells. Biologic therapies are expected to benefit from the rising preference among medical practitioners to implement biologics owing to their established clinical profile. Recently, the approval of new monoclonal antibodies, such as Darzalex, Pomalyst, and Empliciti, is anticipated to drive the growth of this market segment in the near future. Furthermore, in August 2017, the FDA approved chimeric antigen receptor (CAR) T-cell therapy for advanced leukemia, which is currently in clinical trials for multiple myeloma, and its approval is expected to boost the growth of the multiple myeloma treatment market in the near future.

For the purpose of this study, the global multiple myeloma treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America accounted for the largest share in the global multiple myeloma treatment market due to key driving factors such as the rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure. The American Cancer Society estimates that in 2017, about 30,280 new cases will be diagnosed in the United States, and about 12,590 deaths are expected to occur. Thus, the demand for novel drug therapies is expected to increase in the near future. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest growing region due to key driving factors such as the rising prevalence of multiple myeloma in developing countries, increasing awareness associated with an early cancer diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.

Frequently Asked Questions:

The market for Multiple Myeloma Treatment Market is expected to reach USD 21,221.8 Mn By 2025.

The Multiple Myeloma Treatment Market is expected to see significant CAGR growth over the coming years, at 11.0%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, and Juno Therapeutics are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58685
Report Format:   PDF
Pages:   120
Rating:    4.7 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support